Xenomics CEO Dr. Randy White Highlights Breakthrough Tr-DNA Technology in Interview with...

NEW YORK -- Xenomics, Inc (OTCBB:XNOM), a developer of next-generation medical DNA technologies, announced today the online availability of a streaming audio interview recently given by CEO Dr. Randy White to the online investor news source, PRBroadcast.com.

In the interview, Dr. White

Other topics Dr. White addressed include key elements of the Company's business plan and marketing strategy, as well as other details of what lies ahead for Xenomics, to ensure its enduring financial strength.

Tr-DNA refers to particles of DNA that have passed through the body through normal metabolic processes for eventual collection in the urine. Xenomics is creating proprietary medical tests to detect and analyze this genetic material in urine samples to provide detailed and highly accurate information about a range of health conditions, including infectious diseases such as HIV and tuberculosis, fetal genetic health and other medical conditions. Xenomics scientists were the first to detect the presence of Tr-DNA in urine samples and now are using the technology to develop improved, accurate and noninvasive urine-sampling testing methods.

To listen to the interview, please visit http://www.prbroadcast.com, and locate the Xenomics entry on the home page.

About PR Broadcast

The primary objective of PRBroadcast.com is to provide comprehensive coverage of emerging and well established companies listed on the NASDAQ, AMEX, NYSE and Smallcap exchanges, making the information freely available to its subscribers. The staff and affiliates of PRBroadcast.com consist of seasoned financial and marketing professionals such as securities analysts, news release editors, public relations specialists and international multimedia personnel. For more information, visit http://www.prbroadcast.com.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.